Viatris announces the launch of ryzumvl™ (phentolamine ophthalmic solution) 0.75% in the united states

Pittsburgh, april 1, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, today announced the u.s. commercial launch of ryzumvi™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g.

VTRS Ratings Summary

VTRS Quant Ranking